AbbVie Rinvoq shows continued skin repigmentation at 76 weeks

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. SPY

Go back to AbbVie Rinvoq shows continued skin repigmentation at 76 weeks

AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo

October 1, 2026 10:00 AM EDT

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapy Phase 3 Viti-Up-1 and Viti-Up-2 studies show that among patients continuing RINVOQ, the proportions who achieved facial (F-VASI 75) and total body (T-VASI 50) repigmentation continued to increase through week 76 Findings from a phototherapy substudy show numerically higher responses with RINVOQ in combination with narrowband ultraviolet B (NB-UVB) phototherapy than with RINVOQ alone Data are being shared in a late-breaking oral... More